Molecular Signature Predicting Polycythemia Vera Progression

A newly described molecular signature promises to help clinicians predict which patients with polycythemia vera (PV) are most likely to progress to more serious disease. This advance, detailed in a large-scale study of 439 patients, represents a fundamental shift from traditional risk assessment to a biologically informed model. By utilizing a Bayesian approach to identify preferential associations between mutations, researchers identified high molecular risk abnormalities (PV-HMR) consisting of mutations in SRSF2, IDH1/2, EZH2, or NFE2 genes, copy number variations (CNV), and the presence of two or more non-driver mutations.

A Paradigm Shift in Prognostic Precision

This advance matters because the clinical course of PV is notoriously heterogeneous. While some patients remain stable for decades, others face rapid hematologic evolution that is often difficult to predict using standard parameters alone. The ability to identify these higher-risk patients early could fundamentally change monitoring frequencies, treatment choices, and the nature of conversations about long-term planning for both patients and health systems.

Why It Matters

Beyond Clinical Features to Biological Behavior

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by an excessive production of mature blood cells, primarily driven by the JAK2V617F mutation. Although often considered an indolent disease, it is associated with reduced survival compared to the general population due to two primary complications: thromboembolic events and progression to secondary myelofibrosis (SMF) or secondary acute leukemia (sAML).

For decades, clinicians have relied on clinical features such as age, history of thrombosis, and leukocyte counts to estimate risk. However, the Mansier study demonstrates that these traditional markers are imperfect, particularly in predicting transformation. A robust molecular signature adds a necessary layer of precision by reflecting the disease’s underlying genomic behavior.

The Power of Genomic Classification

The study’s 3-tier genomic classification (High-Risk, Intermediate-Risk, and Low-Risk) provides a clearer window into patient outcomes:

• High-Risk (PV-HMR): Associated with the most significant decrease in overall survival (OS) and transformation-free survival (TFS).
• Intermediate-Risk: Primarily defined by TET2 mutations with a variant allele frequency (VAF) ≥ 5.
• Low-Risk: Patients with other molecular profiles who typically enjoy more favorable long-term outcomes.

By outperforming the standard IWG-PV and MIPSS-PV scoring systems in predicting hematologic evolution, this model gives clinicians a tool that looks past outward signs to the genetic drivers of the disease. For patients, knowing their molecular risk could affect how aggressively they are treated, for example, moving from simple phlebotomy to disease-modifying agents earlier in the disease course.

Who It Affects

A Broad Spectrum of Stakeholders

The Patient Experience

Patients living with polycythemia vera (PV) are the most immediate group affected. PV affects approximately 65,000 people in the United States with an annual incidence of 0.5 to 4.0 cases per 100,000 persons. In addition to the overproduction of red blood cells, the production of white blood cells and platelets is also elevated in most people with PV. Due to the overproduction of red blood cells in the bone marrow, an abnormally high number of red blood cells (also known as red blood mass) circulate within the blood. As a result, the blood thickens and increases in volume (a condition called hyperviscosity). Thickened blood may not flow through smaller blood vessels properly.

A variety of symptoms can occur in individuals with PV, including nonspecific symptoms such as headaches, fatigue, weakness, dizziness, itchy skin, an enlarged spleen, a variety of gastrointestinal issues, and the risk of blood clot formation, which may prevent blood flow to vital organs.

Many live for years with a good quality of life on routine therapies. However, the detection of an additional mutation, found in 53.3% of patients in the study, can change the narrative. For the 22.7% of patients harboring two or more mutations, the risk of transformation is significantly higher. Reclassifying these patients as “high risk” can be life-saving by prompting early referral for hematopoietic stem cell transplant evaluation, but it also introduces psychological complexity and scanxiety for patients who may otherwise feel symptomatic.

The Clinical Frontier

Hematologists must now learn to integrate complex NGS (Next-Generation Sequencing) data into real-time decision-making. This requires understanding that not all mutations are equal. For example, the study noted that ASXL1 mutations, often feared in other blood cancers, did not have a pejorative impact on survival when they were isolated (without TET2 or other high-risk mutations). Clinicians must balance these subtle molecular nuances against traditional indicators like age and blood counts.

The Healthcare System

For health systems and payers, the study raises critical questions about the cost-effectiveness of universal genomic testing. If a molecular signature can accurately predict who will progress to costly, life-threatening leukemia, the argument for early, comprehensive sequencing becomes stronger. However, this demands standardized laboratory pipelines for interpreting gene variants and timely reporting to ensure the data is actionable.

What Changes

Biologically Informed Risk Stratification

The integration of molecular profiling means risk assessments will move beyond the surface. Clinicians can now look for specific high-risk markers like SRSF2, which the study found carried a Hazard Ratio (HR) of 8.60 for hematologic transformation. Similarly, NFE2 mutations were associated with a 3.24 HR for decreased transformation-free survival. This data allows for a more graduated management approach:

1. Low-Risk Patients: May be spared intense interventions and frequent, invasive surveillance.
2. High-Risk Patients: May receive targeted therapies (like JAK2 inhibitors or interferon) and more frequent monitoring aimed at detecting progression at a treatable stage.

Updated Laboratory and Payer Infrastructure

Health systems will need to create protocols for sequencing that focus on the specific panel of 36 genes highlighted in the research. This includes detecting Copy Number Variations (CNVs) on chromosomes like 1q, 7, or 20q, as non-9p CNVs were found to be strong markers of poor prognosis. Payers will need to decide if they will cover testing for all newly diagnosed patients or only those with concerning clinical shifts.

Why Integration Will Be Nuanced: Navigating Probability and Ethics

The Challenge of Probabilistic Markers

Translating a molecular signature into routine care is not automatic. Predictive markers are probabilistic. Predictive markers indicate a higher likelihood of an event, not a certainty. For instance, while the PV-HMR signature significantly predicted transformation, the study noted that survival dynamics can vary based on the age of the patient at diagnosis.

The “DTA” Mutation Dilemma

A significant nuance involves the “DTA” mutations (DNMT3A, TET2, ASXL1). These are frequently detected in age-related clonal hematopoiesis (CHIP) in the general population. The study found that DNMT3A mutations were not associated with outcomes, while TET2 mutations only became prognostic when present at a VAF ≥ 5. Without careful interpretation, there is a risk of over-treating patients whose mutations are merely markers of aging rather than disease aggressiveness.

Ethical and Equitable Access

There is a growing risk of a genomic divide. Patients at major academic centers like the 15 French centers in this study have access to centralized, high-throughput sequencing. Ensuring that patients in rural or underserved areas have access to the same level of precision medicine is an ethical mandate for the next decade of hematology.

Clinical Decision-Making and Patient Communication

Clinicians should treat molecular signatures as one vital piece of a larger puzzle. The study utilized a multistate model that included age, gender, history of thrombosis, and blood counts alongside genomic data. This holistic view is essential.

When communicating with patients, clinicians must be clear about what a high-risk profile means. It is not a diagnosis of leukemia, but a signal for increased vigilance. Counseling should address:

• Surveillance intervals: Why a high-risk patient might need blood work every month versus every three months.
• Treatment thresholds: When the presence of an EZH2 or IDH1/2 mutation might tip the scales toward starting interferon alpha.
• Practical concerns: The out-of-pocket costs of specialized testing and the potential for finding germline (inherited) mutations that could affect family members.

Looking Ahead: Toward a Preventive Strategy

In the near term, we can expect guideline updates to incorporate molecular profiling into the initial workup of PV, much like it has been for primary myelofibrosis (PMF). The study’s results were already validated in two independent external cohorts—the Grinfeld et al. cohort and the Saint-Louis Hospital cohort—proving that the “PV-HMR” signature is a reliable predictor across different populations.

Over the medium term, these signatures will likely be used to stratify patients for clinical trials testing new, targeted therapies. For example, if a patient carries an IDH1/2 mutation, they might be eligible for specific inhibitors currently used in other types of AML.

Long-term, the goal is true prevention. Rather than waiting for irreversible marrow damage or leukemic transformation to occur, the identification of a high-risk molecular signature could allow for early interventions that shift the disease course. This requires a coordinated global effort, investment in sequencing infrastructure, thoughtful insurance policies, and a commitment to clinical research that prioritizes long-term patient outcomes over short-term symptom management.

Final Takeaway for Clinicians

The emergence of this molecular signature is a meaningful step toward personalized care in polycythemia vera. While it does not eliminate the uncertainty inherent in chronic blood disorders, it provides a much sharper lens through which to view a patient’s future. By integrating genomic classification with clinical judgment, the medical community can move closer to a future where one-size-fits-most is replaced by the right treatment for the right patient at the right time.

References

1. https://pubmed.ncbi.nlm.nih.gov/40533498/
2. https://pubmed.ncbi.nlm.nih.gov/39556352/
3. https://rarediseases.org/rare-diseases/polycythemia-vera/